← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in nicotine dependence
cytisinicline
N07BA04
Adult Dosing
- Days 1-3: 1.5 mg orally 6 times daily
- Days 4-14: 1.5 mg orally 3 times daily
- Days 15-20: 1.5 mg orally twice daily
- Days 21-25: 1.5 mg orally once daily
- Target quit date is recommended by Day 25 of treatment course
Pediatric Dosing
- Safety and efficacy not established in pediatric patients under 18 years of age
Indications
- Smoking cessation aid to assist in nicotine withdrawal
Mechanism of Action
- Partial agonist at neuronal nicotinic acetylcholine receptors (specifically alpha-4 beta-2 subtype)
- Competitively inhibits binding of nicotine, reducing smoking reward and withdrawal symptoms
Contraindications
- Hypersensitivity to cytisinicline or any component of the formulation
- Severe renal impairment (insufficient data)
Adverse Reactions
- Insomnia
- Abnormal dreams
- Nausea
- Dry mouth
- Dyspepsia
- Headache
- Irritability
Drug Interactions
- Concurrent use with other smoking cessation products (e.g., nicotine replacement therapy) may increase adverse effects
- No clinically significant pharmacokinetic drug interactions identified with CYP450 substrates
Curated Content: Needs Vetting Before Put to Clinical Use